Device Week, Feb. 24, 2022 – CardioMEMS, G7 Data, And Investment Outlook

In this edition of Device Week, Medtech Insight’s Reed Miller chats with UK-based reporter Barnaby Pickering about Abbott’s recent supplementary premarket submission to its CardioMEMS platform, recent safety data for Dexcom’s G7 continuous glucose monitor, and where KPMG expects life sciences investment to be focused in 2022. Medtech Insight articles addressing topics discussed in this episode: -Abbott Hopes To Prevent Heart Failure Hospitalizations With New CardioMEMS HF Labeling - https://medtech.pharmaintelligence.informa.com/MT145103/Abbott-Hopes-To-Prevent-Heart-Failure-Hospitalizations-With-New-CardioMEMS-HF-Labeling -KPMG Speaks On What 2022 Medtech Investment May Look Like -Dexcom Shows Off More G7 Data - https://medtech.pharmaintelligence.informa.com/MT145078/KPMG-Speaks-On-What-2022-Medtech-Investment-May-Look-Like